Articles by Amer Zeidan, MBBS, MHS
The COMMANDS trial evaluated frontline luspatercept in transfusion-dependent patients with lower-risk MDS and anemia.
Moderated by Amer M. Zeidan, MBBS, a panel discusses the critical roles of patient fitness, genetics in AML treatment.
This expert panel shares insights into the latest advancements, clinical challenges in AML and more.
Gain valuable insights from leading experts as they explore how targeted therapies are shaping the future of AML management.
The expert panel discusses current issues in the use of ESAs within MDS management.
In a roundtable discussion, an expert panel discussed how approval of luspatercept has affected frontline MDS treatment.
Amer Zeidan, MBBS, discusses the unanswered questions in research related to myelodysplastic syndromes.
The expert panel describes how having two separate classification systems for MDS affects their clinical practices.
The expert panel discusses how to explain to patients the range of MDS severities and approach lower-risk disease.
The expert panel discusses molecular testing's current place in MDS evaluation and treatment decisions.
In a roundtable discussion, an expert panel describes recent trends in the classification and prognosis of MDS in the clinic.
The panel mainly focused on how to define and classify MDS and CHIP, as well as how to treat low- and high-risk MDS.
Dr. Zeidan will be participating in the myelodysplastic syndromes panel on the second day of the event
Amer Zeidan, MBBS, MHS, reflects on the COMMANDS study that compared luspatercept with epoetin alfa in MDS.
Dr. Zeidan speaks about the rationale behind the trial, the implications of its results, and the next steps.
AML Awareness Month is marked each June.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.